Autoimmune Thyroid Disease and Refractory Chronic Urticaria: Thyroidectomy as a Treatment for Long Standing Remission. A Case Report

One Sentence Summary: A 36-year-old woman with a refractory chronic autoimmune urticaria and a concomitant autoimmune thyroid disease achieved remission from the dermatological point of view after thyroidectomy.

Authors

C. Francés 1, J. Nicolau 1, M. García 2, C. Nadal 3, L. A. Gómez 1, L. Masmiquel 1

Affiliations

1 Endocrinology and Nutrition Department
2 Pathological Anatomy Department
3 Dermatology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain

Abstract

The relationship between autoimmune thyroid disease (AITD) and chronic autoimmune urticaria (CAU) was first described in the decade of the 1980s [1–4]. Since then, multiple cases have been reported, but its pathogenic mechanisms are not well known. CAU is a distressing disease defined as the presence of recurrent, transient and itching maculo-papular skin lesions with or without angioedema, that last more than 6 weeks [5]. Diagnosis is confirmed with an autologous serum skin test, which is considered positive if a papule bigger than 16 mm is obtained [5]. First-line treatment has been based on the use of non-sedating, second-generation antihistamines; following the recommendations of the recent international guidelines, in patients who do not respond to antihistamines at licensed doses, the daily dosage of these drugs can be increased up to 4-fold [6]. However, a significant proportion of patients with chronic urticaria remain poorly controlled; in these cases, alternative therapeutic approaches have to be considered. Nonetheless, even then, a percentage of cases remain symptomatic. We report a case of AITD and refractory CAU with complete and long-standing remission after thyroidectomy. Furthermore, we examine the medical literature for evidences supporting thyroidectomy as a treatment for refractory CAU in patients with thyroid disease.

Introduction

The relationship between autoimmune thyroid disease (AITD) and chronic autoimmune urticaria (CAU) was first described in the decade of the 1980s [1–4]. Since then, multiple cases have been reported, but its pathogenic mechanisms are not well known. CAU is a distressing disease defined as the presence of recurrent, transient and itching maculo-papular skin lesions with or without angioedema, that last more than 6 weeks [5]. Diagnosis is confirmed with an autologous serum skin test, which is considered positive if a papule bigger than 16 mm is obtained [5]. First-line treatment has been based on the use of non-sedating, second-generation antihistamines; following the recommendations of the recent international guidelines, in patients who do not respond to antihistamines at licensed doses, the daily dosage of these drugs can be increased up to 4-fold [6]. However, a significant proportion of patients with chronic urticaria remain poorly controlled; in these cases, alternative therapeutic approaches have to be considered. Nonetheless, even then, a percentage of cases remain symptomatic. We report a case of AITD and refractory CAU with complete and long-standing remission after thyroidectomy. Furthermore, we examine the medical literature for evidences supporting thyroidectomy as a treatment for refractory CAU in patients with thyroid disease.

Case Report

A 36-year-old woman was referred to a dermatology clinic due to pruritic skin lesions. She had no allergies or toxic habits. Her personal clinical history was unremarkable except for 3 episodes of paroxysmal supraventricular tachycardia, which resolved after electric ablation in 2002. The patient started having recurrent maculo-papular lesions which were compatible with urticaria in February 2009. During physical examination, a grade 1 goiter without nodules or palpable adenopathies was found. A pharmacologic, infectious or atopic aetiology was ruled out, and allergy tests were conducted, obtaining negative results. Alfa trypsin and complement factors were normal. Autoantibodies were also determined to discard connective tissue diseases. All the titres were undetectable...
patients with a positive skin test. Interestingly, 6 cases of thyroid function is 4 and 15 times higher, respectively, among the control group (p < 0.0005), and 1% had TGHA in comparison to 0.6% of controls (p < 0.0005). A cutaneous biopsy showed perivascular oedema with a lymphocytic infiltrate, compatible with urticaria (Fig. 1). A positive autologous serum skin test was obtained, and the patient was diagnosed with CAU, starting therapy with desloratadine 2 mg every 8 h.

2 months later, subclinical hyperthyroidism was detected, with TSH 0.180 mcU/ml (NR: 0.55–4.78 mcU/ml), free T4 1.06 ng/dl (NR: 0.89–1.76 ng/dl) and free T3 3.84 pg/ml (NR: 2.3–4.2 pg/ml). The titre of TSH-R antibodies was 7 U/L (NR: 0–10 U/L). A gammagrapy was carried out, showing a diffuse moderate hypercorticating goiter, and ultrasonography reported an enlargement of the superior part of the right lobe (55 × 17 × 19 mm), being the left one of normal size (40 × 16 × 18 mm), without echogenicity alterations, focal lesions or adenopathies. At this point, carbimazole 5 mg per day was started.

Due to the persistence of the urticaria at that moment, 5 mg of prednisone per day were added. Euthyroidism was achieved with carbimazole and lasted 6 months. Afterwards, the patient’s thyroid function worsened with TSH 0.007 mcU/ml, free T3 15.86 pg/ml and free T4 3.84 ng/dl. Treatment with metimazole 15 mg per day was undertaken, obtaining normalization of thyroid function tests 8 weeks later. Subsequently, anti-thyroid drugs were withdrawn. However, during this period, the urticaria worsened progressively, and treatment with desloratadine 5 mg and deflazacort 6 mg during alternate days was tried out, without clinical remission.

6 months later, the patient had a normal thyroid function with persistence of positive thyroid antibodies. Due to the unresponsiveness of CAU, it was decided to perform a total thyroidectomy, and histological examination showed a diffuse hyperplasia in the context of a chronic lymphocitary thyroiditis (Fig. 2). After surgery, treatment with levothyroxine 75 mcg per day was started. Remarkably, urticaria resolved immediately after the thyroidectomy, and the patient remained euthyroid and totally asymptomatic more than 2 years later. At this point, thyroid autoantibodies were negative (last observation: January 16, 2014).

Discussion

A relationship between CAU and AITD has been consistently reported since 1983. In this regard, several studies have shown higher prevalence and titres of thyroid autoantibodies among patients with CAU [5, 7–12]. The greatest study published so far analysing the relationship between CAU and autoimmune disorders, compared 12778 patients with 10714 controls, and thyroid diseases were established as the most common autoimmune disorder in patients with CAU. Hypothyroidism was diagnosed in 9.8% of cases, in comparison to 0.6% of controls (p < 0.0005), and hyperthyroidism in 2.6% vs. 0.09% (p < 0.0005). MGHA were identified in 4.7% of cases in the patient group vs. 0.4% of the control group (p < 0.0005), and 1% had TGHA in comparison to 0.04% of controls (p < 0.0005) [12]. In the same way, O’Donell et al. suggested that the risk for positive MGHA and abnormal thyroid function is 4 and 15 times higher, respectively, among patients with a positive skin test [9]. Interestingly, 6 cases of papillary thyroid carcinoma (PTC) have also been reported in patients with CAU [13–15]. However, thyroid autoimmunity was positive only in one of them. Nevertheless, the fact that thyroidectomy achieved remission in these patients could suggest that other unknown antibodies directed towards thyroid tissue are responsible for the relationship between PTC and CAU.

The autoimmune mechanism by which urticaria is produced is mediated by the humoral immune system. In 30–40% of cases, IgG auto-antibodies against the alpha chain of the high affinity Fc receptor for IgE (FccRIx) have been described [16–18], and in 50% of them, IgG directed towards IgE [19]. These antibodies activate basophils and mast cells to release histamine, and complement fixation augments histamine release by formation of C5a anaphylatoxin [20]. On the other hand, autoimmune thyroiditis is produced due to the action of cellular immunity. In this case, there is a functional defect of suppressor cells and an activation of autoreactive T cells, which cooperate with B cells to stimulate the production of anti-thyroidal antibodies [5]. However, MGHA and TGHA-mediated complement activation has been observed in some studies, and some authors have speculated that different autoantigen-
autoantibody systems (anti-FcRRIα, MGHA) synergize in generating CSa and triggering mast cells and basophils in patients with Hashimoto thyroiditis [21]. As well as this, the cytotoxic T-lymphocyte associated antigen 4 (CTLA4) gene has been shown to be a susceptibility factor for Hashimoto’s thyroiditis and Grave’s disease, and Brozoa et al. hypothesized that it could also have a role in CAU [22]. Furthermore, recently Ramos-Prol et al. have suggested CAU as a possible non-endocrine manifestation of autoimmune polyglandular syndrome type II [23]. However, another hypothesis is that some infectious agents could be involved in the pathogenesis of both chronic urticaria and thyroiditis. Thus, several clinical and experimental observations suggest a relationship between agents like hepatitis C virus, Staphylococcus aureus and Helicobacter pylori with both CAU andAITD [24–27].

It therefore seems logical to state that thyroid examination together with thyroid function tests and autoantibodies titration is advisable in CAU patients.

It is generally accepted that CAU patients should undergo a stepwise treatment, considering that in most cases stepping-up implies an increase in both costs and adverse effects. This process considers leukotriene receptors antagonists or short courses of steroids after high doses of second generation H1 antihistamines. If the disease relapses or persists, needing permanent corticosteroid treatment, the next option should be cyclosporine. Even omalizumab, a monoclonal IgG antibody that binds free IgE and downregulates mast cell function, can be considered [6]. However, nowadays the evidence supporting the use of other immunosuppressive agents, anti-inflammatory drugs, anticoagulants and intravenous immunoglobulins is scarce and insufficient to recommend their routine use.

We report a case of refractory CAU associated toAITD that resolved immediately after thyroidectomy. The patient was first treated with antihistamines and afterwards with corticosteroids, with no response. However, only a second generation antihistamine (desloratadine) was used, and it cannot be excluded that 30 mg/day of cetirizine would have gained a better clinical result. In any case, after observing that the patient had not improved with initial medical treatment, several options were considered. It must be kept in mind that, although heavily disturbing and long-lasting, refractory CAU is not a life-threatening disease and does not imply a risk for organ failure. Therefore, the aim of the treatment should be to control the disease with the least possible adverse effects. It is well known that numerous toxicities, mainly the development of iatrogenic Cushing’s syndrome and inhibition of hypothalamic-pituitary-adrenal function, are related to glucocorticoids. These effects are more common in patients receiving high doses over a long period of time. In this regard, our patient was being treated with 6 mg of deflazacort during alternate days, without response. Thus, the next logical pharmacological option would have been to start omalizumab or a calcineurin inhibitor such as cyclosporine and tacrolimus [6], which are used for approximately 3–6 months. However, in some cases, CAU relapses after drug discontinuation, and long term maintenance therapy has been suggested if this occurs. Important side effects, mainly nephrotoxicity, hypertension, neurotoxicity, metabolic abnormalities and increased risk of malignancy have been reported for both drugs. Therefore, during treatment, blood pressure and kidney and liver function tests must be assessed regularly. Finally, omalizumab has been well tolerated and reduced CAU signs and symptoms in phase III clinical trials [6]. However, after drug discontinuation, symptoms gradually recurred over a period of about 10 weeks. Furthermore, its high costs and limited availability represent a problem in most settings.

On the other hand, Hashimoto thyroiditis usually presents with euthyroidism or hypothyroidism, even though in some cases an initial hyperthyroid phase has been described, which usually does not require medical treatment, and resolves in a hypothyroidism, requiring treatment with levothyroxine. Surgery is only used seldomly, in some patients with goitrous disease and compressive symptoms [32]. However, in GD, once stable, patients can receive definitive therapy with surgery or radiodine. In this case, the course of thyroid autoimmunity may be very different depending on the chosen treatment. Thus, complete removal of thyroid tissue by surgery with its antigenic components results in the disappearance of antibodies to all major thyroid antigens [28]. Accordingly, several studies show a better immunological response in surgical patients when compared with radiodine [29].

As in our patient, 3 cases of immediate CAU remission in the context of AITD have been reported after thyroidectomy (2 Hashimoto’s and one Graves’) [4, 30, 31]. In 2 of these cases autoimmunity had become negative at 6 months (Hashimoto’s) and 18 months follow-up (Graves’). In the third case, autoimmunity after surgery was not recorded, though. 6 other cases of urticaria remission after surgery have also been described in the context of PTC [13–15]. (Table 1). Unfortunately, immunological data have not been reported in all of these PTC patients. On the other hand, one case of CAU 6 years after receiving radiiodine treatment for GD has been reported. In this patient, a concurrent increase of thyroid autoantibodies was detected along with the CAU [23].

Table 1 Case reports of CAU remission after thyroidectomy.

<table>
<thead>
<tr>
<th>Case Number</th>
<th>Author</th>
<th>Year</th>
<th>Age</th>
<th>Gender</th>
<th>Thyropathy</th>
<th>Autoantibodies titer</th>
<th>Follow-up</th>
<th>Time of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cailleba et al.</td>
<td>1993</td>
<td>not recorded</td>
<td>female</td>
<td>Graves’ disease</td>
<td>Anti-Tg 1:40 Anti-TPO &gt; 1:25 600</td>
<td>cured</td>
<td>Anti-Tg negative Anti-TPO 1:6400</td>
</tr>
<tr>
<td>2</td>
<td>Amoroso et al.</td>
<td>1996</td>
<td>60</td>
<td>female</td>
<td>thyroiditis</td>
<td>Anti-Tg 3 Anti-TPO &gt; 70 IU/ml and 3.0 IU/mL</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>3</td>
<td>Raza et al.</td>
<td>2004</td>
<td>29</td>
<td>female</td>
<td>thyroiditis</td>
<td>Anti-Tg 3 Anti-TPO &gt; 70 IU/ml</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>4</td>
<td>Manganoni et al.</td>
<td>2007</td>
<td>39</td>
<td>female</td>
<td>TPC</td>
<td>negative</td>
<td>cured</td>
<td>Anti-Tg 3 Anti-TPO &gt; 70 IU/ml and 3.0 IU/mL</td>
</tr>
<tr>
<td>5</td>
<td>Manganoni et al.</td>
<td>2007</td>
<td>32</td>
<td>female</td>
<td>TPC</td>
<td>negative</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>6</td>
<td>Manganoni et al.</td>
<td>2007</td>
<td>61</td>
<td>female</td>
<td>TPC</td>
<td>negative</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>7</td>
<td>Manganoni et al.</td>
<td>2007</td>
<td>42</td>
<td>female</td>
<td>TPC</td>
<td>negative</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>8</td>
<td>Ozkaya et al.</td>
<td>2011</td>
<td>25</td>
<td>female</td>
<td>TPC</td>
<td>negative</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
<tr>
<td>9</td>
<td>Kartal et al.</td>
<td>2012</td>
<td>25</td>
<td>male</td>
<td>TPC</td>
<td>Anti-Tg 300 IU/ml</td>
<td>cured</td>
<td>Anti-Tg 1:6-400</td>
</tr>
</tbody>
</table>

In conclusion, we describe a case of CAU associated to AITD that resolved immediately after thyroidectomy with a long lasting remission. Other cases of CAU remission after thyroidectomy have been reported in the literature. These cases together with epidemiological, clinical and experimental data suggest that these 2 entities are closely related and that thyroidectomy could benefit the course of CAU by removing thyroid antigens. Fur- thermore, thyroidectomy should be considered in patients with CAU and AITD when third and fourth-line treatment options are being needed for the treatment of the skin lesions (Fig. 3).

Conflict of interest: The authors declare no conflict of interest.

References


2 Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. Journal of Investigational Allergology and Clinical Immunology 1989; 84.


14 Ozkaya E, Elinc-Aslan MS, Yazici S. Aquagenic urticaria and syncope associated with occult papillary thyroid carcinoma and improvement after total thyroidectomy. Archives of Dermatology 2011; 147.


16 Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgE anti-FcεRia (α-subunit) in chronic urticaria. Journal of Allergy and Clinical Immunology 1998; 101.


